Drug intelligence / Profile preview

lactobacillus paracasei

Development stage: Phase 4
Lead developer: Mengniu
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Topical, Intravaginal

Overview

lactobacillus paracasei is a probiotic bacterial species used as an orally administered live or heat-treated microbial intervention in clinical studies across allergic, gastrointestinal, metabolic, and oncology-supportive settings. Its therapeutic rationale is as a microbiome-directed agent that may modulate host immune responses, epithelial barrier function, and intestinal microbial ecology rather than acting through a single defined receptor target. Publicly described programs and studies include strain-specific products such as GM-080, PC-01, and LPB27, with reported investigation in atopic dermatitis, asthma, functional dyspepsia, obesity, postoperative recovery, type 1 diabetes, and as an adjunct with PD-1 blockade in esophageal squamous cell carcinoma. The evidence base is heterogeneous and appears strain- and formulation-dependent, with some studies reporting clinical benefit while others did not show added efficacy.

Other names: Lactobacillus paracasei副干酪乳杆菌

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on lactobacillus paracasei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus paracasei.

Explore the full profile